Published in Hospital Business Week, July 6th, 2008
"FASN is highly expressed in breast cancer and most common human carcinomas. Several compounds can inhibit FASN, although the degree of specificity of this inhibition has not been addressed. We have tested the effects of C75 and (-)-epigallocatechin-3-gallate (EGCG) on fatty acid metabolism pathways, cellular proliferation, induction of apoptosis and cell signalling in human breast cancer cells....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week